First Tracks Biotherapeutics (TRAX) director converts 6,030 RSUs into common stock

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

First Tracks Biotherapeutics director Dennis M. Fenton exercised restricted stock units into common shares as part of his equity compensation. On June 15, 2026, 6,030 RSUs converted into 6,030 shares of common stock at no cash cost, bringing his direct holdings to 10,995 shares. The RSUs vested in full on that date, with no remaining RSU balance reported.

Insider Trade Summary

6,030 shares exercised/converted

Mixed 2 txns

Insider FENTON DENNIS M

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	6,030	$0.00	--
Exercise	Common Stock	6,030	$0.00	--

Holdings After Transaction: Restricted Stock Unit — 0 shares (Direct, null); Common Stock — 10,995 shares (Direct, null)

Footnotes (1)

Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

RSUs exercised: 6,030 shares Shares received: 6,030 common shares Post-transaction holdings: 10,995 shares +1 more

4 metrics

RSUs exercised 6,030 shares Restricted Stock Units converted to common stock on June 15, 2026

Shares received 6,030 common shares Shares issued upon RSU settlement at $0.0000 per share

Post-transaction holdings 10,995 shares Common stock directly held by Dennis M. Fenton after transaction

Exercise price $0.0000 per share RSUs settled for no cash consideration

Key Terms

Restricted Stock Unit, contingent right, vests as to 100%, Form 4

4 terms

Restricted Stock Unit financial

"Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

contingent right financial

"Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."

vests as to 100% financial

"The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/17/2026 - 04:06 PM Accepted by SEC EDGAR 06/17/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FENTON DENNIS M

(Last)

(First)

(Middle)

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
First Tracks Biotherapeutics, Inc. [ TRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/15/2026		M		6,030	A	$0⁽¹⁾	10,995	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	⁽¹⁾	06/15/2026		M			6,030	⁽²⁾	⁽²⁾	Common Stock	6,030	$0	0	D

Explanation of Responses:

1. Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

2. The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Ajim Tamboli, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did First Tracks Biotherapeutics (TRAX) report for Dennis M. Fenton?

First Tracks Biotherapeutics reported that director Dennis M. Fenton exercised 6,030 restricted stock units into 6,030 common shares. This was a compensation-related RSU vesting rather than an open-market stock purchase or sale.

How many First Tracks Biotherapeutics (TRAX) shares does Dennis M. Fenton hold after this Form 4?

After the June 15, 2026 RSU conversion, Dennis M. Fenton directly holds 10,995 shares of First Tracks Biotherapeutics common stock. This reflects his equity position following the vesting and settlement of 6,030 restricted stock units.

Did Dennis M. Fenton buy or sell TRAX shares on the market in this filing?

No open-market buying or selling occurred in this filing. Dennis M. Fenton’s Form 4 shows only the exercise and settlement of 6,030 restricted stock units into common shares at no cash cost, a standard equity-compensation event.

What are the terms of Dennis M. Fenton’s restricted stock units at First Tracks Biotherapeutics?

Each restricted stock unit represents a contingent right to receive one share of First Tracks Biotherapeutics common stock for no consideration. The RSUs in this filing vested 100% on June 15, 2026, provided Fenton continued to serve the company through that vesting date.

Were any restricted stock units left unvested for Dennis M. Fenton after June 15, 2026?

According to the Form 4 data, the restricted stock unit position in this award dropped to zero after June 15, 2026. That indicates the 6,030 RSUs covered by this filing fully vested and were settled into common shares on that date.